Evidence map›Paper›PMID 39820635›Full record

ArticleThe oncologist2025

Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study.

Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, Jasnoor Malhotra, Daniela V Castro, Ameish Govindarajan, William Hiromi Fuzita, Marcos Vinicius da Silva França, Andressa Cardoso de Azeredo, Gabriel Marques Dos Anjos and 8 more

Abstract readMulticenter Study
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Models, outcomes, barriers, and facilitators of supportive care in cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Cristiane Decat BergerotOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Paulo Gustavo BergerotOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Errol J PhilipUniversity of California Los Angeles, Los Angeles, CA 90095, United States.
Jasnoor MalhotraDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Daniela V CastroDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Ameish GovindarajanMemorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
William Hiromi FuzitaOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Marcos Vinicius da Silva FrançaOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Andressa Cardoso de AzeredoOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Gabriel Marques Dos AnjosOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Romildo de AraujoOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
JoAnn HsuDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Neal ChawlaDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Alex Chehrazi-RaffleDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Marco Murilo BusoOncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, SP 04543-906, Brazil.
Bechara SaabMobio Interactive Pte. Ltd., Gateway West 189720, Singapore.
Linda E CarlsonDepartment of Oncology, University of Calgary Cumming School of Medicine, Calgary, Alberta T2N 4N1, Canada.
Sumanta K PalDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Barry Hoeven Memorial Kidney Cancer ResearchKure It Cancer ResearchNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPatients with metastatic renal cell carcinoma (mRCC) experience emotional distress and limited supportive care access. This study assesses a mindfulness app's feasibility, acceptability, and preliminary efficacy in improving emotional symptoms, trait mindfulness, and overall quality of life for patients with mRCC on immunotherapy.

methodsThis multinational study recruited patients with mRCC undergoing immunotherapy from Brazil and the United States. Participants were required to engage in mindfulness app-based activities for 20-30 min daily, at least 4 days per week, over a 4-week period. Assessments were conducted at weeks 0, 2, 4, and 12 to evaluate emotional symptoms (PROMIS-Anxiety and Depression, Fear of Cancer Recurrence-7), fatigue (Brief Fatigue Inventory), trait mindfulness (Mindfulness Attention Awareness Scale), and quality of life (Functional Assessment of Chronic Illness Therapy-General). Self-reported data were used to assess adherence. Linear mixed-effects models were used to evaluate changes over time for the measured outcomes.

resultsAmong 50 patients with mRCC, the feasibility of this intervention was demonstrated; 96% of patients were assessed at week 4, with high adherence rates reported by 75% of patients. Participants expressed positive feedback on the smartphone-based approach. Significant improvements were observed in emotional symptoms, fatigue, and quality of life scores from baseline to post-intervention (P = .001 for each), suggesting the positive impact of this intervention.

conclusionOur findings provide encouraging evidence for the feasibility and acceptability of a mindfulness app-based intervention among patients with mRCC. This intervention may offer a viable and accessible means of providing psychosocial support to patients with mRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMindfulnessMobile ApplicationsAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedQuality of Lifedigital healthemotional distressfatiguekidney cancermind-body therapiesmindfulness

Identifiers

PMID39820635
PMCPMC11740315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.